China SXT Pharmaceuticals (SXTC) Total Current Liabilities (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Total Current Liabilities for 9 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities fell 27.66% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (down 27.66% YoY) and the FY2026 annual result came in at $4.3 million, down 27.66% from the prior year.
• Total Current Liabilities retreated to $4.3 million in Q1 2026 per SXTC's latest filing, from $6.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for SXTC reached as high as $17.1 million in Q1 2022 and fell as low as $4.3 million in Q1 2026.
• A 5-year average of $9.9 million and a median of $8.9 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities surged 70.26% — and 2025, when it plunged 61.94%.
• Year by year, Total Current Liabilities stood at $7.3 million in 2022, then advanced by 26.17% to $9.2 million in 2023, then jumped by 70.26% to $15.7 million in 2024, then tumbled by 61.94% to $6.0 million in 2025, then declined by 27.04% to $4.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $4.3 million, $6.0 million, and $6.0 million for Q1 2026, Q3 2025, and Q1 2025 respectively.